NASDAQ:ATHE Alterity Therapeutics (ATHE) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free ATHE Stock Alerts $2.51 +0.25 (+11.06%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$2.26▼$2.7550-Day Range$1.66▼$2.9452-Week Range$1.55▼$5.41Volume87,800 shsAverage Volume77,675 shsMarket Capitalization$11.72 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Alterity Therapeutics alerts: Email Address Alterity Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside178.9% Upside$7.00 Price TargetShort InterestHealthy1.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.58 out of 5 starsMedical Sector449th out of 916 stocksPharmaceutical Preparations Industry187th out of 416 stocks 3.5 Analyst's Opinion Consensus RatingAlterity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlterity Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.09% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently increased by 290.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlterity Therapeutics does not currently pay a dividend.Dividend GrowthAlterity Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHE. Previous Next 1.7 News and Social Media Coverage News SentimentAlterity Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alterity Therapeutics this week, compared to 0 articles on an average week.Search Interest5 people have searched for ATHE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows1 people have added Alterity Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.14% of the stock of Alterity Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Alterity Therapeutics are expected to grow in the coming year, from ($0.25) to ($0.13) per share.Price to Book Value per Share RatioAlterity Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Alterity Therapeutics Stock (NASDAQ:ATHE)Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Read More ATHE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHE Stock News HeadlinesApril 17, 2024 | finance.yahoo.comAlterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingApril 10, 2024 | globenewswire.comAlterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024April 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 5, 2024 | finance.yahoo.comAlterity Therapeutics Limited (ATHE)March 26, 2024 | globenewswire.comAlterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundMarch 24, 2024 | morningstar.comAlterity Therapeutics Ltd ADR ATHEMarch 22, 2024 | seekingalpha.comATHE Alterity Therapeutics LimitedMarch 22, 2024 | wsj.comAlterity Therapeutics Ltd. ADRApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 23, 2024 | msn.comAlterity Therapeutics drops on capital raiseFebruary 22, 2024 | benzinga.comAlterity Therapeutics Stock (NASDAQ:ATHE), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingFebruary 20, 2024 | globenewswire.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingJanuary 29, 2024 | finance.yahoo.comAlterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekJanuary 22, 2024 | finance.yahoo.comAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesDecember 21, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressDecember 4, 2023 | marketwatch.comAlterity Therapeutics Shares Up Fivefold on New Parkinson's Drug DataDecember 4, 2023 | msn.comWhy Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today?December 4, 2023 | finance.yahoo.comBiotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial DataDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s DiseaseNovember 27, 2023 | finance.yahoo.comAlterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNovember 22, 2023 | finance.yahoo.comAlterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The MomentNovember 22, 2023 | msn.comAlterity Therapeutics, Edesa Biotech among healthcare moversNovember 22, 2023 | marketwatch.comAlterity Therapeutics ADRs Shares Dive 31% on Raised CapitalNovember 16, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434November 16, 2023 | finance.yahoo.comAlterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434See More Headlines Receive ATHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATHE CUSIPN/A CIK1131343 Webwww.alteritytherapeutics.com Phone(139) 349-4906Fax61-3-9348-0377Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+178.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick RatioN/A Sales & Book Value Annual Sales$3.37 million Price / Sales3.48 Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book0.66Miscellaneous Outstanding Shares4,670,000Free Float2,859,000Market Cap$11.72 million OptionableNot Optionable Beta0.94 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Geoffrey Paul Kempler B.Sc. (Age 69)Co-Founder & Non-Executive Chairman Comp: $204.84kDr. David A. Stamler M.D. (Age 63)Chief Executive Officer Comp: $605.41kMr. Phillip Allen Hains BBus(Acc) (Age 65)C.A., M.B.A., CFO & Company Secretary Dr. Rudolph Emile Tanzi Ph.D. (Age 65)Chief Scientific Advisor and Member of Research & Development Advisory Board Dr. Steven D. TargumChief Medical AdvisorDr. Robert ChernyHead of ResearchMore ExecutivesKey CompetitorsElevai LabsNASDAQ:ELABMoleculin BiotechNASDAQ:MBRXAkari TherapeuticsNASDAQ:AKTXGuardion Health SciencesNASDAQ:GHSIAeterna ZentarisNASDAQ:AEZSView All Competitors ATHE Stock Analysis - Frequently Asked Questions Should I buy or sell Alterity Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHE shares. View ATHE analyst ratings or view top-rated stocks. What is Alterity Therapeutics' stock price target for 2024? 1 brokers have issued 12-month price objectives for Alterity Therapeutics' stock. Their ATHE share price targets range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 178.9% from the stock's current price. View analysts price targets for ATHE or view top-rated stocks among Wall Street analysts. How have ATHE shares performed in 2024? Alterity Therapeutics' stock was trading at $2.49 at the beginning of the year. Since then, ATHE shares have increased by 0.8% and is now trading at $2.51. View the best growth stocks for 2024 here. Are investors shorting Alterity Therapeutics? Alterity Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 90,300 shares, an increase of 290.9% from the March 31st total of 23,100 shares. Based on an average daily volume of 82,300 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.1% of the company's shares are sold short. View Alterity Therapeutics' Short Interest. When did Alterity Therapeutics' stock split? Shares of Alterity Therapeutics reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Alterity Therapeutics? Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATHE) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
